Our Pricing

Saxenda vs Wegovy: Complete Switch & Save Guide

Published on: June 03, 2026

Considering switching from Saxenda to Wegovy UK? At Cured Pharmacy, our UK-registered clinical team has supported hundreds of patients transitioning from daily liraglutide injections to once-weekly semaglutide, achieving better weight loss outcomes with improved convenience. This comprehensive guide explains the clinical evidence, cost differences, and safe transition protocols approved by UK prescribers.

Why UK Patients Are Switching from Saxenda to Wegovy

Saxenda (liraglutide) was the first GLP-1 receptor agonist licensed by the MHRA for weight management in the UK, requiring daily subcutaneous injections at doses up to 3mg. Wegovy (semaglutide) represents a newer generation of GLP-1 therapy, offering once-weekly administration and significantly greater weight loss efficacy in head-to-head clinical trials [1].

In the STEP 2 trial comparing semaglutide 2.4mg weekly against liraglutide 3mg daily, patients on Wegovy achieved an average 9.6% total body weight loss compared to 3.4% with Saxenda over 68 weeks [1]. This threefold difference in efficacy, combined with the convenience of weekly rather than daily injections, has driven thousands of UK patients to request switching from Saxenda to Wegovy through their prescribers.

Beyond efficacy, cost considerations matter. At Cured Pharmacy, Wegovy starts from £79.00 per month with transparent upfront pricing shown before your free consultation, often representing better value than daily Saxenda therapy when comparing cost per kilogram of weight lost [2]. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) ensures every patient receives genuine UK-licensed medicines dispensed to the highest regulatory standards.

Saxenda vs Wegovy: Clinical Efficacy Comparison

Both medications work by mimicking GLP-1, a natural hormone that regulates appetite and blood sugar levels. However, semaglutide (Wegovy) has a longer half-life and higher receptor binding affinity than liraglutide (Saxenda), producing more sustained appetite suppression and greater metabolic effects [2].

The STEP 1 trial demonstrated that adults treated with Wegovy 2.4mg weekly achieved an average 14.9% body weight reduction over 68 weeks, with 86.4% of participants losing at least 5% of their baseline weight [3]. By comparison, the SCALE Obesity and Prediabetes trial showed Saxenda 3mg daily produced an average 8.0% weight loss over 56 weeks, with 63.2% achieving the 5% threshold [4].

UK prescribers typically consider switching from Saxenda to Wegovy when patients have plateaued on maximum-dose liraglutide therapy, experience injection fatigue from daily administration, or require greater weight loss to reach clinical targets. All prescription decisions require individual clinical assessment by a UK-registered prescriber based on your medical history, current medications, and weight management goals.

Gastrointestinal Tolerability Profile

Both medications commonly cause nausea, vomiting, diarrhoea, and constipation, particularly during dose escalation phases. In clinical trials, approximately 44% of Wegovy patients and 39% of Saxenda patients reported nausea [1][4]. However, because Wegovy uses a gradual dose escalation protocol over 16-20 weeks compared to Saxenda's 5-week titration, some patients transitioning from Saxenda may experience improved gastrointestinal tolerance due to their prior GLP-1 exposure.

Your UK prescriber will determine the appropriate starting dose when switching from Saxenda to Wegovy based on your current liraglutide dose, tolerability history, and time since last Saxenda injection. Most patients do not restart at the lowest Wegovy dose if they have been tolerating maximum-dose Saxenda, though individual protocols vary subject to prescriber clinical judgement.

How to Switch from Saxenda to Wegovy Safely

The transition from daily Saxenda to weekly Wegovy requires careful timing and dose selection to maintain therapeutic GLP-1 levels while minimising side effects. UK prescribers typically recommend stopping Saxenda and starting Wegovy within 24-48 hours to avoid a gap in GLP-1 receptor stimulation that could trigger rebound appetite [5].

Most patients who have been on Saxenda 3mg daily for several weeks can begin Wegovy at the 0.5mg or 1mg weekly dose rather than the initial 0.25mg starter dose, as their GLP-1 receptors are already downregulated and tolerant to the medication class. However, this decision must be made by your UK prescriber during your clinical assessment, as individual factors including kidney function, previous side effect severity, and concurrent medications influence the safest transition protocol.

At Cured Pharmacy, our online consultation takes under 3 minutes and asks specific questions about your current Saxenda dose, duration of therapy, and tolerability to help our UK prescribers determine the optimal Wegovy starting dose for your switch. All consultations are reviewed by GMC-registered doctors or GPhC-registered prescribing pharmacists within 24 hours, with discreet next-day delivery available across the UK once your prescription is approved.

Monitoring During the Transition Period

During the first 4-8 weeks after switching from Saxenda to Wegovy, UK clinical guidelines recommend monitoring for changes in blood glucose (particularly in patients with type 2 diabetes), gastrointestinal symptoms, heart rate, and signs of pancreatitis including severe abdominal pain [5]. Patients should maintain a food diary and track weekly weight measurements to assess early response to semaglutide therapy.

If you experience persistent vomiting, severe abdominal pain, visual changes, or symptoms of thyroid nodules during your transition, contact your prescriber immediately. While serious adverse events are rare, early identification and management optimise safety outcomes. Our clinical team at Cured Pharmacy remains available via phone (+44 116 4646009) for any medication queries after your prescription is dispensed.

Cost Comparison: Saxenda vs Wegovy UK Pricing

Medication costs represent a significant consideration for UK patients managing chronic weight, as neither Saxenda nor Wegovy are routinely available on NHS prescription for weight management alone outside specialist obesity services. Private prescription costs vary across UK pharmacies, making price transparency essential for informed treatment decisions.

At Cured Pharmacy, Wegovy starts from £79.00 per month with all prices displayed upfront before you begin your free consultation—no hidden fees, no surprise charges at checkout. This transparent pricing model, combined with our Lowest Prices Guaranteed commitment, ensures you receive genuine UK-licensed semaglutide at competitive rates without compromising on pharmaceutical quality or clinical oversight.

When comparing cost-effectiveness between Saxenda and Wegovy, consider both the monthly prescription price and the average weight loss achieved per pound spent. Clinical trial data suggests Wegovy produces approximately 1.86 times greater weight loss than Saxenda over comparable timeframes [1], meaning even if monthly costs were similar, the cost per kilogram of weight lost favours semaglutide therapy for most patients. Your prescriber can discuss individualised cost-benefit analysis during your consultation.

Injection Technique and Administration Differences

Patients switching from Saxenda to Wegovy will notice several practical differences in injection technique and pen device design. Saxenda uses a multi-dose pen requiring daily injections, with each pen containing 18mg of liraglutide (6 doses at 3mg). Wegovy comes in single-dose prefilled pens, with each pen containing one weekly dose that automatically delivers the correct amount when the injection button is pressed and held for approximately 5-10 seconds.

Both medications are injected subcutaneously into the abdomen, thigh, or upper arm, rotating injection sites weekly to reduce lipodystrophy risk. The Wegovy pen is generally considered more user-friendly by patients who have used both devices, as it eliminates the need to dial doses and reduces the risk of dosing errors. Comprehensive injection training is provided with your first Wegovy prescription, and our pharmacy team can answer technique questions to ensure proper administration.

Storage requirements differ slightly: Saxenda pens in use can be kept at room temperature (below 30°C) for up to 30 days, while Wegovy pens should be stored in the refrigerator (2-8°C) until use, though they can tolerate room temperature for up to 28 days if needed. Always check the patient information leaflet supplied with your medication for complete storage and handling instructions specific to your prescribed product.

Managing Injection Site Reactions

Mild injection site reactions including redness, itching, or small lumps occur in approximately 2-5% of patients on GLP-1 therapies [3][4]. These reactions are typically self-limiting and resolve within 2-4 days. Patients switching from Saxenda to Wegovy may notice fewer injection site issues due to reduced injection frequency (weekly versus daily), allowing more time for tissue recovery between injections.

To minimise injection site reactions, ensure your Wegovy pen has reached room temperature before injecting (remove from refrigerator 30 minutes prior), clean the injection site with an alcohol wipe and allow to dry completely, and avoid injecting into areas with scars, moles, or broken skin. If you develop persistent injection site reactions, bruising, or signs of infection, contact your prescriber for clinical assessment.

Starting Your Switch to Wegovy at Cured Pharmacy

Transitioning from Saxenda to Wegovy through Cured Pharmacy begins with our free online consultation, designed by UK prescribers to gather the clinical information needed for safe prescribing decisions. The assessment takes under 3 minutes and covers your current liraglutide dose, weight loss progress, medical history, current medications, and any side effects experienced on Saxenda.

Once submitted, your consultation is reviewed by a UK-registered prescriber (GMC-registered doctor or GPhC prescribing pharmacist) typically within 24 hours. If Wegovy is clinically appropriate and safe based on your individual circumstances, your prescription is sent electronically to our GPhC-registered pharmacy (9012511) for dispensing. We supply only genuine UK-licensed Wegovy manufactured by Novo Nordisk, sourced through authorised UK pharmaceutical wholesalers.

Your medication is dispatched in 100% discreet packaging via tracked courier, with next-day delivery available across mainland UK. Each shipment includes the patient information leaflet, injection technique guide, and sharps disposal information. Our clinical team remains available for ongoing medication queries throughout your treatment journey—simply call (+44 116 4646009) or email our pharmacy team for expert support from UK-registered healthcare professionals.

All prescription medications dispensed by Cured Pharmacy require clinical assessment and approval by a UK prescriber. We cannot supply Wegovy or any prescription-only medicine without a valid prescription issued following appropriate clinical consultation. This regulatory requirement protects patient safety and ensures every treatment decision is made by a qualified healthcare professional based on individual medical circumstances.

Scientific References

1. Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., & Lingvay, I. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
2. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., Rudofsky, G., Tadayon, S., Wadden, T. A., & Dicker, D. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
3. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
4. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., & Wilding, J. P. H. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
5. Medicines and Healthcare products Regulatory Agency (MHRA). (2023). Semaglutide (Wegovy) 2.4 mg: Summary of Product Characteristics. GOV.UK. Retrieved from https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy and Saxenda are prescription-only medicines that can only be supplied following appropriate clinical consultation and prescriber approval. Individual results may vary. Weight loss medications work best when combined with a reduced-calorie diet and increased physical activity.